Future Research Objectives and Questions for Radiologically Isolated Syndrome: Darin Okuda, MD, FAAN, FANA

Video

The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center discussed ways to build off the ARISE study and the unanswered questions regarding radiologically isolated syndrome. [WATCH TIME: 3 minutes]

WATCH TIME: 3 minutes

"We were not trying to prove a point that dimethyl fumarate could be absolutely superior to placebo within this trial. We wanted to demonstrate as an international consortium was that, is there an opportunity to intervene earlier, knowing that early treatment has an impact on long-term outcomes?"

Over the years, there have been dramatic improvements to the treatment options available for patients with relapsing multiple sclerosis (MS), including the introduction of several new disease-modifying therapies. There has been accumulating evidence to suggest that earlier initiation of these therapeutics provides the best chance at reducing inflammation and damage to nerve cells, thus slowing the progression of the disease. Identified in 2009, radiologically isolated syndrome (RIS), considered the precursor to MS, represents an intriguing area of research interest considering its potential impacts in the conversion to MS.

While not all cases of RIS develop MS, the clinical community, including Darin Okuda, MD, FAAN, FANA, have hypothesized that earlier intervention of this condition could have significant biologic effects. Recently, Okuda and his colleagues published results from the ARISE study (NCT92639542), a randomized controlled study that was the first to show a disease-modifying effect in patients with RIS. Using dimethyl fumarate (Tecfidera; Biogen), a previously approved DMT for relapsing MS, findings showed an 82% reduction in risk of first clinical demyelinating event over a 96-week treatment period (hazard ratio, 0.18; 95% CI, 0.05-0.63; P = .007).

These findings were significant, as they represented the first disease-modifying effect seen in this patient group. Okuda, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center, believes these findings open the door to a world of new research. In an interview with NeurologyLive®, he provided context on the next steps following ARISE, the questions surrounding RIS that still need to be answered, and the ongoing efforts exploring drugs besides dimethyl fumarate in RIS.

REFERENCE
1. Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. Ann Neurol. Published online November 18, 2022. doi:10.1002/ana.26555
Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.